Yahoo Web Search

Search results

1. www.ncbi.nlm.nih.gov › pmc › articlesAngiotensin Receptor-Neprilysin Inhibitor (ARNI) and Cardiac ...

   www.ncbi.nlm.nih.gov › pmc › articles

   Aug 20, 2021 · This review summarizes the possible link between ARNI and cardiac arrhythmias and discusses potential underlying mechanisms, providing novel insights about the therapeutic role and safety profile of ARNI in the cardiovascular system.

   • Author: Henry Sutanto, Dobromir Dobrev, Jordi Heijman
   • DOI: 10.3390/ijms22168994

   • Publish Year: 2021
   • Publication: Int J Mol Sci. 2021 Aug; 22(16): 8994.

2. www.ncbi.nlm.nih.gov › pmc › articlesARNi: A Novel Approach to Counteract Cardiovascular Diseases

   www.ncbi.nlm.nih.gov › pmc › articles

   Apr 28, 2019 · Indeed, a new class of drug, the angiotensin receptor–neprilysin inhibitors (ARNi), has the ability to counteract the effects of angiotensin II as well as to increase the activity of NPs. ARNi have already been proven to be effective in the treatment of heart failure with reduced ejection fraction.

   • Author: Massimo Volpe, Speranza Rubattu, Allegra Battistoni

   • Publish Year: 2019

3. Videos

   • 

     4:41

     youtube.com

     Hypertrophic Cardiomyopathy: What is it and how is it treated?

     16 Apr 2019

     99.9K views

   • 

     14:55

     youtube.com

     Hypertrophic Cardiomyopathy (HCM): Innovative Options for Treatment

     26 Aug 2020

     11.7K views

   • 

     8:43

     youtube.com

     Hypertrophic Cardiomyopathy Made Easy | (Includes Hypertrophic Obstructive Cardiomyopathy & SAM)

     26 Jan 2022

     54.9K views

   View all

4. www.nature.com › articles › s41440/021/00706-1Angiotensin receptor-neprilysin inhibitors: Comprehensive ...

   www.nature.com › articles › s41440/021/00706-1

   Jul 21, 2021 · Angiotensin receptor-neprilysin inhibitors (ARNIs) are a new class of cardiovascular agents characterized by their dual action on the major regulators of the cardiovascular system,...

   • Author: Koichi Yamamoto, Hiromi Rakugi

   • Publish Year: 2021

5. www.ncbi.nlm.nih.gov › pmc › articlesPractical Recommendations for the Use of Angiotensin Receptor ...

   www.ncbi.nlm.nih.gov › pmc › articles

   Jun 29, 2023 · Recommendation: ARNI can be prescribed to non-dialysis patients with CKD and heart failure. The use of ARNI in such patients reduces cardiovascular risk and improves eGFR compared to ACEI/ARBs.

   • DOI: 10.1007/s40119-023-00323-8
   • Published: 2023/09

   • Publication: Cardiol Ther. 2023 Sep; 12(3): 445-471.

6. e-heartfailure.org › pdf › 10Angiotensin Receptor-Neprilysin Inhibition (ARNI) in Heart ...

   e-heartfailure.org › pdf › 10

   evidence that sacubitril-valsartan, an angiotensin receptor-neprilysin inhibitor (ARNI), is superior to an ACEI in reducing mortality and HF hospitalization and in improving quality of life in patients with stage C HFrEF. In these trials, sacubitril-valsartan was found to be safe and well tolerated.

   • Author: Barry Greenberg

   • Publish Year: 2020

7. www.jacc.org › doi › 10What Explains the Benefits of ARNI Therapy in Heart Failure?

   www.jacc.org › doi › 10

   The stimulus for neurohormonal activation appears to be a threat to the arterial blood pressure related to a reduction in cardiac output leading to a baroreceptor-mediated activation of several vasoconstrictor and vasodilator neurohormones; similar to the primitive evolutionary response that helps to maintain the arterial pressure during blood ...

8. People also ask

   Should Arni therapy be used in patients with heart failure?

   • Ongoing trials will assess the role for ARNI therapy in patients with heart failure with preserved ejection fraction (HFpEF) and in the post-myocardial infarction setting. Future studies should comprehensively assess predictors of response to ARNI therapy.

   Reverse Cardiac Remodeling and ARNI Therapy - Springer

   link.springer.com/article/10.1007/s11897-021-00501-6

   See all results for this question

   Does Arni reduce ventricular arrhythmias?

   • Moreover, the paper highlights the role of ARNI in heart failure management, with numerous clinical trials that have demonstrated its effectiveness in reducing cardiovascular death or heart failure hospitalization, enhancing quality of life, and diminishing the risk of ventricular arrhythmias.

   Practical Recommendations for the Use of Angiotensin Receptor

   www.ncbi.nlm.nih.gov/pmc/articles/PMC10423183/

   See all results for this question

   Can an Arni treat hypertension clinically?

   • To decide whether to apply an ARNI to treat hypertension clinically, it is important to understand the potential properties of the drug in modulating multiple factors inside and outside the cardiovascular system beyond its effect on reducing peripheral blood pressure.

   Angiotensin receptor-neprilysin inhibitors: Comprehensive review a…

   www.nature.com/articles/s41440-021-00706-1

   See all results for this question

   What is the role of Arni in cardiovascular disease?

   • The promising roles of ARNI in cardiovascular diseases. ARNI (e.g., sacubitril/valsartan) inhibits neprilysin (NEP) and the binding of angiotensin II to its receptor (AT1R), preventing the activation of intracellular signaling cascades.

   Angiotensin Receptor-Neprilysin Inhibitor (ARNI) and Cardiac

   www.ncbi.nlm.nih.gov/pmc/articles/PMC8396594/

   See all results for this question

   Can Arni improve peritoneal dialysis patients' heart failure symptoms?

   • Twenty-one HFpEF patients on peritoneal dialysis patients from a Chinese study with ARNI was found to have a tendency to enhance cardiac function and to considerably improve heart failure symptoms and signs as well as the levels of heart failure markers .

   Practical Recommendations for the Use of Angiotensin Receptor

   www.ncbi.nlm.nih.gov/pmc/articles/PMC10423183/

   See all results for this question

   Should Arni be used in HF patients?

   • Use of ARNI in such patients reduces cardiovascular risk and improves eGFR compared to ACEI/ARBs. ARNI dose adjustment is not required in HF patients with mild to moderate renal impairment. Depending on the patient's blood pressure, a loading dose of 25–50 mg BID is advised in severe renal impairment.

   Practical Recommendations for the Use of Angiotensin Receptor

   www.ncbi.nlm.nih.gov/pmc/articles/PMC10423183/

   See all results for this question

9. link.springer.com › article › 10Reverse Cardiac Remodeling and ARNI Therapy | Current Heart ...

   link.springer.com › article › 10

   • Cached

   Jan 22, 2021 · Much of the observed clinical benefit of sacubitril/valsartan therapy in patients with HFrEF is likely related to significant reverse cardiac remodeling. Ongoing trials will assess the role for ARNI therapy in patients with heart failure with preserved ejection fraction (HFpEF) and in the post-myocardial infarction setting.